147 related articles for article (PubMed ID: 19066166)
1. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
2. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
4. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
5. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
[TBL] [Abstract][Full Text] [Related]
6. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
7. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
8. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
9. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
10. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
[TBL] [Abstract][Full Text] [Related]
12. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.
Torres A; Alshalalfa M; Tomlins SA; Erho N; Gibb EA; Chelliserry J; Lim L; Lam LLC; Faraj SF; Bezerra SM; Davicioni E; Yousefi K; Ross AE; Netto GJ; Schaeffer EM; Lotan TL
J Mol Diagn; 2017 May; 19(3):475-484. PubMed ID: 28341589
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
16. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
17. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
[TBL] [Abstract][Full Text] [Related]
19. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
20. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]